[go: up one dir, main page]

WO1996040058A3 - Liquid fluorocarbon emulsion as a vascular nitric oxide reservoir - Google Patents

Liquid fluorocarbon emulsion as a vascular nitric oxide reservoir Download PDF

Info

Publication number
WO1996040058A3
WO1996040058A3 PCT/US1996/009549 US9609549W WO9640058A3 WO 1996040058 A3 WO1996040058 A3 WO 1996040058A3 US 9609549 W US9609549 W US 9609549W WO 9640058 A3 WO9640058 A3 WO 9640058A3
Authority
WO
WIPO (PCT)
Prior art keywords
nitric oxide
liquid fluorocarbon
fluorocarbon emulsion
oxide reservoir
utilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/009549
Other languages
French (fr)
Other versions
WO1996040058A2 (en
Inventor
Stephen F Flaim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alliance Pharmaceutical Corp
Original Assignee
Alliance Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alliance Pharmaceutical Corp filed Critical Alliance Pharmaceutical Corp
Priority to JP9501847A priority Critical patent/JPH11507351A/en
Priority to AU61615/96A priority patent/AU718120B2/en
Priority to EP96919220A priority patent/EP0831776A2/en
Priority to IL12226196A priority patent/IL122261A/en
Publication of WO1996040058A2 publication Critical patent/WO1996040058A2/en
Publication of WO1996040058A3 publication Critical patent/WO1996040058A3/en
Priority to NO975322A priority patent/NO975322L/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Biocompatible fluorocarbon emulsions are utilized to inhibit the removal of endogenously produced nitric oxide from the bloodstream, and to thereby inhibit vascular stenosis, vasoconstriction, and any other physiological condition or disorder arising in whole or in part from a deficiency of endogenous nitric oxide. Liquid fluorocarbon emulsions are also utilized to enhance the effectiveness of intravenously administered hemoglobin by limiting the availability of met-hemoglobin forming plasma-dissolved nitric oxide.
PCT/US1996/009549 1995-06-07 1996-06-07 Liquid fluorocarbon emulsion as a vascular nitric oxide reservoir Ceased WO1996040058A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP9501847A JPH11507351A (en) 1995-06-07 1996-06-07 Liquid fluorocarbon emulsion as a vascular nitric oxide reservoir
AU61615/96A AU718120B2 (en) 1995-06-07 1996-06-07 Liquid fluorocarbon emulsion as a vascular nitric oxide reservoir
EP96919220A EP0831776A2 (en) 1995-06-07 1996-06-07 Liquid fluorocarbon emulsion as a vascular nitric oxide reservoir
IL12226196A IL122261A (en) 1995-06-07 1996-06-07 Liquid fluorocarbon emulsions for treatment of conditions resulting from a deficiency in endogenous nitric oxide
NO975322A NO975322L (en) 1995-06-07 1997-11-19 Liquid hydrocarbon emulsion as a vascular nitric oxide reservoir

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/501,976 US5726209A (en) 1995-06-07 1995-06-07 Liquid fluorocarbon emulsion as a vascular nitric oxide reservoir
US08/501,976 1995-06-07

Publications (2)

Publication Number Publication Date
WO1996040058A2 WO1996040058A2 (en) 1996-12-19
WO1996040058A3 true WO1996040058A3 (en) 1997-02-13

Family

ID=23995789

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/009549 Ceased WO1996040058A2 (en) 1995-06-07 1996-06-07 Liquid fluorocarbon emulsion as a vascular nitric oxide reservoir

Country Status (12)

Country Link
US (1) US5726209A (en)
EP (1) EP0831776A2 (en)
JP (1) JPH11507351A (en)
KR (1) KR19990022586A (en)
CN (1) CN1192136A (en)
AU (1) AU718120B2 (en)
CA (1) CA2221965A1 (en)
HU (1) HUP9900900A2 (en)
IL (1) IL122261A (en)
NO (1) NO975322L (en)
PL (1) PL323821A1 (en)
WO (1) WO1996040058A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869539A (en) * 1996-04-17 1999-02-09 Board Of Regents, The University Of Texas System Emulsions of perfluoro compounds as solvents for nitric oxide (NO)
US6103275A (en) * 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
RU2161122C1 (en) * 1999-09-10 2000-12-27 Институт молекулярной генетики РАН Method of accelerating oxidation of nitrogen monoxide in heterogeneous medium
CN101646442B (en) * 2007-02-23 2013-09-04 21世纪国际新技术株式会社 Therapeutic or prophylactic agent for vasoconstriction
US8906855B2 (en) 2007-12-22 2014-12-09 Vivacelle Bio, Inc. Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
US8618056B2 (en) 2007-12-22 2013-12-31 Cuthbert O. Simpkins Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
WO2010087986A2 (en) * 2009-01-30 2010-08-05 Simpkins Cuthbert O Resuscitation fluid

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993002653A1 (en) * 1991-08-08 1993-02-18 Segel Leigh D Fluorocarbon blood substitute
WO1994000180A1 (en) * 1992-06-25 1994-01-06 The General Hospital Corporation Methods and devices for relaxing smooth muscle contractions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987154A (en) * 1986-01-14 1991-01-22 Alliance Pharmaceutical Corp. Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal use
US4927623A (en) * 1986-01-14 1990-05-22 Alliance Pharmaceutical Corp. Dissolution of gas in a fluorocarbon liquid
US4865836A (en) * 1986-01-14 1989-09-12 Fluoromed Pharmaceutical, Inc. Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport
US4781676A (en) * 1987-02-20 1988-11-01 Air Products And Chemicals, Inc. Interstitial administration of perfluorochemical emulsions for reoxygenation of hypoxic tumor cells
US4866096A (en) * 1987-03-20 1989-09-12 Air Products And Chemicals, Inc. Stable fluorochemical aqueous emulsions
US4895876A (en) * 1987-03-20 1990-01-23 Air Products And Chemicals, Inc. Concentrated stable fluorochemical aqueous emulsions containing triglycerides
US4993415A (en) * 1988-08-19 1991-02-19 Alliance Pharmaceutical Corp. Magnetic resonance imaging with perfluorocarbon hydrides
US5628930A (en) * 1992-10-27 1997-05-13 Alliance Pharmaceutical Corp. Stabilization of fluorocarbon emulsions
ATE194769T1 (en) * 1993-10-08 2000-08-15 Us Health USE OF NITROGEN OXIDE RELEASING COMPOUNDS AS MEDICINAL AGENTS FOR RADIATION SENSITIZATION FOR HYPOXIC CELLS
AU704173B2 (en) * 1993-11-02 1999-04-15 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College, The Use of nitric oxide releasing compounds as protective agents in ischemia reperfusion injury

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993002653A1 (en) * 1991-08-08 1993-02-18 Segel Leigh D Fluorocarbon blood substitute
WO1994000180A1 (en) * 1992-06-25 1994-01-06 The General Hospital Corporation Methods and devices for relaxing smooth muscle contractions

Also Published As

Publication number Publication date
US5726209A (en) 1998-03-10
JPH11507351A (en) 1999-06-29
WO1996040058A2 (en) 1996-12-19
PL323821A1 (en) 1998-04-27
IL122261A0 (en) 1998-04-05
NO975322L (en) 1998-01-09
IL122261A (en) 2001-09-13
KR19990022586A (en) 1999-03-25
EP0831776A2 (en) 1998-04-01
AU6161596A (en) 1996-12-30
NO975322D0 (en) 1997-11-19
CN1192136A (en) 1998-09-02
MX9709695A (en) 1998-06-28
HUP9900900A2 (en) 1999-08-30
CA2221965A1 (en) 1996-12-19
AU718120B2 (en) 2000-04-06

Similar Documents

Publication Publication Date Title
CA2164291A1 (en) Methods and pharmaceutical compositions useful for treating neurological disorders
KR910016317A (en) Method for increasing delivery by iontophoresis and composition used therein
CA2090404A1 (en) Nonaqueous fluorinated drug delivery vehicle suspensions
ATE185548T1 (en) USE OF N-ARYLMETHYLENE ETHYLENEDIAMINE DIACETATE, N-ARYLMETHYLENE IMINODIACETATE OR N,N'-DIARYLMETHYLENE ETHYLENEDIAMINE DIACETATE AGAINST OXIDATIVE STRESS
EP1820862A3 (en) Medical preparations for the treatment of alpha-galactosidase a deficiency
CA2212511A1 (en) Clot resistant multiple lumen catheter
ATE167631T1 (en) COMPOSITIONS OF A THROMBOLYTIC SUBSTANCE AND ANTICOAGULANTS, AND USES THEREOF
CA2382013A1 (en) Pharmaceutical solutions of levosimendan
CA2110161A1 (en) Medetomidine preparations for transdermal administration
WO1996040058A3 (en) Liquid fluorocarbon emulsion as a vascular nitric oxide reservoir
EP0300680A3 (en) Doublestranded rna correction of abnormalities in circulating immune complexes and monocyte function
CA2132544A1 (en) Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
CA2311128A1 (en) Composition with azelaic acid
WO2000010533A3 (en) Compositions and methods for treating intracellular infections
CA2280773A1 (en) Methods for the administration of amifostine
EP0147185A3 (en) Therapeutic use of cytidyl disphosphocholine to increase neuronal acetylcholine
EP0784983A3 (en) Use of extracellular hemoglobin
US20050020662A1 (en) Inhibition of PKC to treat permability failure
Zalewski et al. Protection of the ischemic myocardium during percutaneous transluminal coronary angioplasty
Metwally et al. Effect of cimetidine, bicarbonate and glucose on the bioavailability of different formulations of praziquantel
RU97110475A (en) FROLOVA OINTMENT-BALM FOR TREATING BURNS AND INFECTED RAS OF VARIOUS ETHIOLOGY
Loeliger Does dipyridamole have antithrombotic potential?
KR900017599A (en) Pharmaceutical composition for tumor treatment
ITRM930034A0 (en) ACTIVE AGENT TO REDUCE THE BLOOD LEVEL OF GLUCOCORTICOIDS AND PREVENT BRAIN DISORDERS DUE TO STRESS AND SENILITY.
Katz et al. Failure of low dose nifedipine to improve exercise tolerance in stable angina

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96195948.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 310760

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2221965

Country of ref document: CA

Ref document number: 2221965

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 1997 501847

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1997/009695

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1019970709067

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1996919220

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996919220

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019970709067

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1019970709067

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1996919220

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996919220

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)